ABSTRACT
No disponible
Subject(s)
Humans , Dermatitis, Contact/diagnosis , Eczema/diagnosis , Pruritus/etiology , Risk FactorsABSTRACT
No disponible
Subject(s)
Humans , Female , Young Adult , Psoriasis/complications , Alopecia/etiology , Adalimumab/therapeutic use , Cicatrix/physiopathologyABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Skin Diseases, Eczematous/complications , Skin Diseases, Eczematous/diagnosis , Skin Diseases, Eczematous/pathology , Eczema/complications , Eczema/diagnosis , Eczema/pathology , Lymphoma, Large-Cell, Anaplastic/diagnosis , Lymphoma, Large-Cell, Anaplastic/pathology , Ki-1 Antigen/isolation & purification , Hyperkeratosis, Epidermolytic/complications , Hyperkeratosis, Epidermolytic/pathology , Positron-Emission Tomography/instrumentation , Positron-Emission Tomography/methods , Immunohistochemistry/instrumentation , Immunohistochemistry/methods , ImmunohistochemistrySubject(s)
Eczema/etiology , Ichthyosis/etiology , Lymphoma, Large-Cell, Anaplastic/diagnosis , Adult , Eczema/diagnosis , Eczema/pathology , Female , Humans , Ichthyosis/diagnosis , Ichthyosis/pathology , Ki-1 Antigen/metabolism , Lymphoma, Large-Cell, Anaplastic/complications , Lymphoma, Large-Cell, Anaplastic/pathologyABSTRACT
INTRODUCCIÓN: La condrodermatitis nodular del hélix (CNH) es un proceso idiopático, degenerativo y doloroso que afecta a la piel y al cartílago del hélix o del antéhelix. Recientemente se ha descrito la utilidad de la nitroglicerina (NTG) tópica a 2% en el tratamiento de la CNH con buenos resultados, aunque con una tasa de efectos secundarios en el 17% de los casos. Es probable que a una concentración menor se pueda mantener el mismo efecto mejorando la tolerancia. Nuestra finalidad fue evaluar la efectividad y seguridad de la NTG tópica al 0,2% para el tratamiento de la CNH. MATERIAL Y MÉTODOS: Se llevó a cabo un estudio observacional retrospectivo entre los años 2012 y 2014 en 2 centros hospitalarios españoles. La efectividad se determinó a través de la evaluación clínica, realizada mediante seguimiento fotográfico, y de los síntomas de la lesión, medido mediante una escala numérica verbal. RESULTADOS: Veintinueve pacientes recibieron el tratamiento, de los cuales el 93% manifestaron una mejoría clínica con una duración media del tratamiento de 1,8 meses y un tiempo de seguimiento medio en los pacientes respondedores de 5,9 meses. La tolerancia fue buena en general en todos los casos. CONCLUSIÓN: La NTG tópica al 0,2% se plantea como una opción conservadora, efectiva y bien tolerada para el tratamiento de la condrodermatitis nodular del hélix que mejora tanto la apariencia clínica como la sintomatología en la mayoría de los pacientes
BACKGROUND AND OBJECTIVE: Chondrodermatitis nodularis helicis (CNH) is a painful idiopathic degenerative condition involving the skin and cartilage of the helix or antihelix of the ear. Topical nitroglycerin 2% is a relatively recent treatment option for CNH that has produced good results, although with adverse effects (17% of cases). The use of a lower concentration would probably achieve similar results with fewer adverse effects. The aim of this study was to evaluate the effectiveness and safety of topical nitroglycerin 0.2% in the treatment of CNH. MATERIAL AND METHODS: We performed a retrospective observational study of patients treated in 2 Spanish hospitals between 2012 and 2014. The effectiveness of treatment was determined by clinical photography and assessment of symptoms using a verbal numerical rating scale. RESULTS: Of the 29 patients treated, 93% showed clinical improvement. In the group of responders, mean treatment duration was 1.8 months and mean follow-up was 5.9 months. Overall tolerance was good in all cases. CONCLUSION: Topical nitroglycerin 0.2% is an effective and well-tolerated conservative treatment option that improves the appearance of lesions and provides symptomatic relief in the majority of patients with CNH
Subject(s)
Female , Humans , Male , Glycerol , Glycerol/pharmacology , Ear Auricle/abnormalities , Ear Auricle/injuries , Cardiovascular Diseases/complications , Cardiovascular Diseases/diagnosis , Breast Neoplasms/diagnosis , Therapeutics/methods , Observational Study , Glycerol/metabolism , Glycerol/therapeutic use , Ear Auricle/metabolism , Ear Auricle , Cardiovascular Diseases/nursing , Cardiovascular Diseases , Breast Neoplasms/pathology , Therapeutics/classification , Spain/ethnology , Retrospective StudiesABSTRACT
BACKGROUND AND OBJECTIVE: Chondrodermatitis nodularis helicis (CNH) is a painful idiopathic degenerative condition involving the skin and cartilage of the helix or antihelix of the ear. Topical nitroglycerin 2% is a relatively recent treatment option for CNH that has produced good results, although with adverse effects (17% of cases). The use of a lower concentration would probably achieve similar results with fewer adverse effects. The aim of this study was to evaluate the effectiveness and safety of topical nitroglycerin 0.2% in the treatment of CNH. MATERIAL AND METHODS: We performed a retrospective observational study of patients treated in 2 Spanish hospitals between 2012 and 2014. The effectiveness of treatment was determined by clinical photography and assessment of symptoms using a verbal numerical rating scale. RESULTS: Of the 29 patients treated, 93% showed clinical improvement. In the group of responders, mean treatment duration was 1.8 months and mean follow-up was 5.9 months. Overall tolerance was good in all cases. CONCLUSION: Topical nitroglycerin 0.2% is an effective and well-tolerated conservative treatment option that improves the appearance of lesions and provides symptomatic relief in the majority of patients with CNH.
Subject(s)
Cartilage Diseases/drug therapy , Dermatitis/drug therapy , Dermatologic Agents/therapeutic use , Ear Diseases/drug therapy , Nitroglycerin/therapeutic use , Administration, Cutaneous , Adult , Aged , Aged, 80 and over , Dermatologic Agents/administration & dosage , Dermatologic Agents/adverse effects , Dose-Response Relationship, Drug , Ear Auricle/drug effects , Ear Auricle/pathology , Ear Cartilage/drug effects , Ear Cartilage/pathology , Female , Humans , Male , Middle Aged , Nitroglycerin/administration & dosage , Nitroglycerin/adverse effects , Retrospective Studies , Treatment OutcomeABSTRACT
BACKGROUND: Biobadaderm is the Spanish registry of psoriasis patients receiving systemic treatment in clinical practice. OBJECTIVE: To compare the safety of biologics and classic systemic treatment. METHODS: Prospective cohort of patients receiving biologics and classic systemic therapies between 2008 and 2013 in 12 hospitals are included. We registered demographic data, diagnoses, comorbidities, treatments and adverse events (AE). We obtained raw relative risks (RR) for specific AE. Multivariate analysis consisted of Cox models adjusting for age, gender, chronic hepatic disease and previous cancer. RESULTS: A total of 1030 patients received biologics (2061 AE in 3681 person-years), 926 patients classic systemic drugs (1015 AE in 1517 person-years). Ninety-three per cent of AE in both groups were non-serious, 6% serious and 0.003% fatal. The age- and gender-adjusted hazard ratio of AE was lower in the biologics group [hazard ratio 0.6 (95% CI: 0.5-0.7)].We found no differences in rates of serious and mortal AE. Some system organ class AE rates differed between both groups. As limitations: Prescription bias might affect the incidence of AE in both groups. Association of drug and AE was based on timing: associations might not be causal. CONCLUSION: Patients receiving biologics had lower risk of AE. We did not find differences in the risk of serious or fatal AE.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Biological Products/adverse effects , Immunosuppressive Agents/adverse effects , Keratolytic Agents/adverse effects , Psoriasis/drug therapy , Acitretin/adverse effects , Adalimumab , Adult , Aged , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized/adverse effects , Cyclosporine/adverse effects , Etanercept , Female , Humans , Immunoglobulin G/adverse effects , Infliximab , Male , Methotrexate/adverse effects , Middle Aged , Proportional Hazards Models , Prospective Studies , Receptors, Tumor Necrosis Factor , Registries , Risk Assessment , Spain , UstekinumabABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Ultrasonography/adverse effects , Ultrasonography , Ultrasonography/trends , Ultrasonography/instrumentation , Ultrasonography/classification , Biopsy/methodsABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Middle Aged , Skin Ulcer/chemically induced , Methotrexate/adverse effects , Myeloablative Agonists/therapeutic use , Edema/chemically induced , BiopsyABSTRACT
Although potatoes represent a large part of diets worldwide, adverse reactions to them are considered uncommon and usually result from ingestion, mainly in children. In contrast, immediate reactions to contact with raw potato has been reported more frequently in adults, usually in the form of an oral contact dermatitis or contact urticaria, but also may manifest as asthma, rhinoconjunctivitis, wheezing or even anaphylaxis. We report a case of non-occupational allergic contact urticaria caused by raw potato, which we then documented by prick testing.
Subject(s)
Dermatitis, Allergic Contact/etiology , Hand Dermatoses/etiology , Solanum tuberosum/adverse effects , Urticaria/etiology , Adult , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Occupational/diagnosis , Diagnosis, Differential , Female , Friction , Hand Dermatoses/diagnosis , Hot Temperature , Humans , Intradermal Tests , Plant Proteins/adverse effects , Protein Denaturation , Pruritus/etiologyABSTRACT
Granular parakeratosis is a rare entity that results from an acquired disorder of keratinization. Clinically presents as dark erythematous plaques, occasionally pruritic, that usually involve the axilla and other intertriginous areas. The pathology is characteristic and consists of thickening of the stratum corneum with compact parakeratosis and retention of keratohyaline granules, whereas the stratum granulosum is preserved. The etiology is unknown although some factors such as irritating physical or chemical agents have been implicated. Treatment response is variable. We report a new case in a 50-year-old woman with brownish and hyperkeratotic plaques on both axillae, of two years duration, with a compatible pathology that showed a favorable response to tacalcitol.
